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Stellingen behorende bij het proefschrift
EXPANDING THE MUTATION SPECTRUM 
IN FSHD AND ICF SYNDROME
1. Recessive mutations in DNMT3B cause ICF1 syndrome, dominant mutations in 
DNMT3B combined with medium-short permissive D4Z4 repeat arrays can cause 
FSHD2 (this thesis)
2. FSHD1 and FSHD2 represent opposite extremes of a disease continuum (this thesis)
3. D4Z4 methylation has predictive value for determining the functional consequences 
of SMCHD1 variants of unknown significance (this thesis)
4. In the absence of exonic SMCHD1 variants in FSHD2 patients, it is important to screen 
for SMCHD1 hemizygosity or intronic SMCHD1 variants (this thesis). 
5. The gender bias in ICF2 patients suggests that pathogenic ZBTB24 variants are more 
deleterious for females. (this thesis)
6. Concerning D4Z4 and DUX4: More is less (Adapted from P.E. Thijssen, Thesis, Leiden 
University, 2016)
7. To find novel deep intronic mutations and determine their pathogenicity it is crucial 
to combine sequencing of intronic regions with studies addressing the mRNA 
molecules produced in affected tissue from patients. (Drago et al. Hum Genet 2017)
8. Mutations in SMCHD1 thus contribute to distinct phenotypic spectra, from craniofacial 
malformation and reproductive disorders to muscular dystrophy, which we speculate 
to be consistent with oligogenic mechanisms resulting in pleiotropic outcomes. 
(Shaw et al. Nat Genet 2017) 
9. The complex, but highly overlapping, pathophysiology suggests that all ICF genes 
act in common or converging pathways involved in immunity, chromatin regulation 
and development. (Thijssen et al. Nat Com 2015)
10. Determining the epigenetic signatures that are predictive of disease severity and 
identifying the spectrum of disease modifiers in FSHD are vital to the development of 
effective therapies. (Himeda et al. Antioxid. Redox Signal. 2015)
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